What can we help you find?

August 7, 2017 6:00 am ET

European Facility Will Boost Global Vaccine Production Capacity

MSD Animal Health, known as Merck Animal Health in the United States and
Canada, today announced plans to purchase a new manufacturing facility
in Krems an der Donau, Austria with the intention to expand its global
vaccine manufacturing capacity. The facility, currently owned by Shire
plc., was built in 2002 and will add to the company’s impressive global
manufacturing capabilities.

“This new manufacturing site is ideally located in central Europe. It
provides MSD Animal Health additional manufacturing resources and
advanced technology platforms to meet the growing demand for our vaccine
products that prevent disease and keep animals healthy while positioning
us for strong long-term growth,” stated Joseph Morrissey, senior vice
president, operations, MSD Animal Health.

“We are excited to expand our footprint to Krems,” stated Dr.
Hans-Günther Dittrich, vice president, Europe, Russia, North Africa,
Middle East region. “Krems is the home to several distinct universities,
and a rich tradition as an economic center for bio-pharmaceuticals. It
is a great opportunity for us to tap into the innovative science in the
area.”

MSD Animal Health has a substantial global manufacturing footprint and
is a leader in animal health vaccines with a range of global vaccines
products for animal health diseases.

MSD Animal Health intends to immediately begin renovating the facility
and expects to be ready for production in the coming years. Additional
terms of the deal will not be disclosed.

About MSD Animal Health

For more than a century, MSD, a leading global biopharmaceutical
company, has been inventing for life, bringing forward medicines and
vaccines for many of the world’s most challenging diseases. MSD Animal
Health, known as Merck Animal Health in the United States and Canada, is
the global animal health business unit of MSD. Through its
commitment to the Science of Healthier Animals™, MSD Animal
Health offers veterinarians, farmers, pet owners and governments one of
the widest range of veterinary pharmaceuticals, vaccines and health
management solutions and services. MSD Animal Health is dedicated to
preserving and improving the health, well-being and performance of
animals. It invests extensively in dynamic and comprehensive R&D
resources and a modern, global supply chain. MSD Animal Health is
present in more than 50 countries, while its products are available in
some 150 markets. For more information, visit www.msd-animal-health.com
or connect with us on LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2016 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Merck
Media
Pam Eisele, 267-305-3558
Pamela.eisele@merck.com
or
Noreen Verbrugge, 973-937-5450
Noreen.verbrugge@merck.com
or
Investor Relations
Amy Klug, 908-740-1898
Amy.klug@merck.com